title: Abciximab does not prevent ischemic lesions related to cerebral angiography: a randomized placebo-controlled trial.
abstract: BACKGROUND
  To assess the efficiency of IIb/IIIa platelet receptor inhibition by abciximab in the prevention of silent embolism during digital subtraction angiography.
  
  
  METHODS
  In this randomized, double-blind, prospective study, pre- and postangiographic diffusion-weighted magnetic resonance imaging (DWI) of 184 participants was evaluated for the occurrence of silent embolism.
  
  
  RESULTS
  No significant relationship was found between the patients receiving abciximab before digital subtraction angiography (15 of 90; 16.7%) and patients in the placebo group (16 of 94; 17.0%) regarding postangiographic appearance of silent emboli (p = 0.9).
  
  
  CONCLUSIONS
  IIb/IIIa receptor inhibition by abciximab does not diminish the occurrence of silent embolism during digital subtraction angiography. Our findings indicate that solid blood clots are not the origin of hyperintense lesions observed on DWI and enhance the role of alternative mechanisms.
authors.affiliation: Department of Neuroradiology, Medical Faculty Mannheim, University of Heidelberg, Germany. caro.brockmann@gmx.de
authors.forename: Carolin
authors.initials: C
authors.lastname: Brockmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Hoefer
authors.forename: Michael
authors.initials: M
authors.lastname: Diepers
authors.forename: Eva
authors.initials: E
authors.lastname: Neumaier-Probst
authors.forename: Ingo
authors.initials: I
authors.lastname: Noelte
authors.forename: Marc-Alexander
authors.initials: MA
authors.lastname: Brockmann
authors.forename: Christel
authors.initials: C
authors.lastname: Weiss
authors.forename: Christoph
authors.initials: C
authors.lastname: Groden
authors.forename: Johann
authors.initials: J
authors.lastname: Scharf
mesh_terms: D000077284:Abciximab; D015901:Angiography, Digital Subtraction / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D002533:Cerebral Angiography / Q000009:adverse effects*; D038524:Diffusion Magnetic Resonance Imaging; D004311:Double-Blind Method; D005260:Female; D005858:Germany; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D020766:Intracranial Embolism / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D015990:Placebo Effect; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011446:Prospective Studies; D012307:Risk Factors; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab